DNLI vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about Denali Therapeutics Inc. (DNLI) and Eli Lilly and Company (LLY).

Performance

DNLI vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Denali Therapeutics Inc. (DNLI) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

DNLI vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
DNLI Denali Therapeutics Inc.	16.29%	-18.99%	-5.03%	-22.83%	-37.65%	-46.75%	380.83%	-15.68%	32.10%	-27.09%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	16.14%	40.45%	-2.30%

Fundamentals

Market Cap DNLI : $3.37B LLY : $825.96B
EPS DNLI : -$2.96 LLY : $22.96
PB Ratio DNLI : 3.32 LLY : 31.13
Total Revenue (TTM) DNLI : $0.00 LLY : $65.18B
Gross Profit (TTM) DNLI : $0.00 LLY : $54.62B
EBITDA (TTM) DNLI : -$544.31M LLY : $27.94B

Returns By Period

In the year-to-date period, DNLI achieves a 16.29% return, which is significantly higher than LLY's -14.27% return.

DNLI

• 1D: 6.19%
• 1M: -9.35%
• YTD: 16.29%
• 6M: 32.23%
• 1Y: 41.23%
• 3Y*: -5.90%
• 5Y*: -19.25%
• 10Y*: —

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DNLI vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNLI

DNLI Risk / Return Rank: 64
DNLI Sharpe Ratio Rank: 65
DNLI Sortino Ratio Rank: 64
DNLI Omega Ratio Rank: 60
DNLI Calmar Ratio Rank: 68
DNLI Martin Ratio Rank: 64

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNLI vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Denali Therapeutics Inc. (DNLI) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DNLI	LLY	Difference
Sharpe ratio Return per unit of total volatility	0.67	0.29	+0.39
Sortino ratio Return per unit of downside risk	1.34	0.69	+0.65
Omega ratio Gain probability vs. loss probability	1.16	1.10	+0.07
Calmar ratio Return relative to maximum drawdown	1.28	0.42	+0.86
Martin ratio Return relative to average drawdown	2.48	1.02	+1.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DNLI vs. LLY - Sharpe Ratio Comparison

The current DNLI Sharpe Ratio is 0.67, which is higher than the LLY Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of DNLI and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DNLI	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.67	0.29	+0.39
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.31	1.23	-1.53
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.02	0.56	-0.58

Correlation

The correlation between DNLI and LLY is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DNLI vs. LLY - Dividend Comparison

DNLI has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DNLI Denali Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

DNLI vs. LLY - Drawdown Comparison

The maximum DNLI drawdown since its inception was -87.74%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for DNLI and LLY.

Drawdown Indicators

	DNLI	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-87.74%	-68.24%	-19.50%
Max Drawdown (1Y) Largest decline over 1 year	-23.42%	-30.26%	+6.84%
Max Drawdown (5Y) Largest decline over 5 years	-85.38%	-34.48%	-50.90%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-79.48%	-17.00%	-62.48%
Average Drawdown Average peak-to-trough decline	-50.89%	-19.25%	-31.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.07%	12.39%	-0.32%

Volatility

DNLI vs. LLY - Volatility Comparison

Denali Therapeutics Inc. (DNLI) has a higher volatility of 22.33% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that DNLI's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DNLI	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.33%	9.04%	+13.29%
Volatility (6M) Calculated over the trailing 6-month period	43.63%	26.21%	+17.42%
Volatility (1Y) Calculated over the trailing 1-year period	61.96%	42.44%	+19.52%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.61%	32.14%	+30.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	65.46%	29.80%	+35.66%

Financials